E-viri
Recenzirano
Odprti dostop
-
Forlenza, Christopher J.; Rosenzweig, Jaclyn; Mauguen, Audrey; Buhtoiarov, Ilia; Cuglievan, Branko; Dave, Hema; Deyell, Rebecca J.; Flerlage, Jamie E.; Franklin, Anna K.; Krajewski, Jennifer; Leger, Kasey J.; Marks, Lianna J.; Norris, Robin E.; Pacheco, Martha; Willen, Faye; Yan, Adam Paul; Harker-Murray, Paul D.; Giulino-Roth, Lisa
Blood advances, 07/2023, Letnik: 7, Številka: 13Journal Article
•Among 67 children with relapsed/refractory HL treated with ASCT and brentuximab vedotin consolidation, the 3-year PFS was 85%.•Brentuximab vedotin consolidation in pediatric patients with relapsed/refractory HL is associated with a favorable safety profile. Display omitted Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with ∼50% of patients experiencing a subsequent relapse. The anti-CD30 antibody–drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults with high-risk relapsed/refractory HL. Data on brentuximab vedotin as consolidative therapy after ASCT in pediatric patients with HL are extremely limited, with data of only 11 patients reported in the literature. We performed a retrospective analysis of 67 pediatric patients who received brentuximab vedotin as consolidation therapy after ASCT for the treatment of relapsed/refractory HL to describe the experience of this regimen in the pediatric population. This is the largest cohort reported to date. We found that brentuximab vedotin was well tolerated with a safety profile similar to that of adult patients. With a median follow-up of 37 months, the 3-year PFS was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after ASCT for children with relapsed/refractory HL.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.